Drugs / Rabbit Anti-Human T-Lymphocyte Globulin
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT03393611 Background | Nov 2012 → Aug 2021 | acute myeloid leukemia, myelodysplastic syndrome | Weill Medical College of Cornell University | Completed | No outcome recorded |
| Phase 4 | NCT03828682 Background | Jun 2019 → Jul 2021 | immunodeficiency disease | Simon Tremblay, PharmD, PhD | Unknown | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Rabbit Anti-Human T-Lymphocyte Globulin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03393611 ↗ |